Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


An Expert’s Guide to EHA 2022: A Preview of the Top Abstracts

Stéphane de Botton, MD

Associate Professor
Department of Clinical Hematology
Université Paris Saclay
Paris, France
Department of Hematology
Gustave Roussy
Villejuif, France

Stéphane de Botton, MD: consultant/advisor/speaker: AbbVie, Astellas Pharma, Bristol-Myers Squibb, GlaxoSmithKline, Jazz Pharmaceuticals, SERVIER, Syndax; research funding: Auron Therapeutics; Forma Therapeutics; travel/accommodations/expenses: AbbVie; Bristol-Myers Squibb; SERVIER.

View ClinicalThoughts from this Author

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD: consultant: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, MSD, Novartis, Regeneron, Roche, Sanofi, SecuraBio, Takeda.

View ClinicalThoughts from this Author

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Alessandra Tedeschi, MD: consultant: AbbVie, AstraZeneca, BeiGene, Janssen.

View ClinicalThoughts from this Author

Released: June 20, 2022

Important results from many clinical trials in hematologic malignancies were discussed at the 2022 European Hematology Association (EHA) annual meeting. Below, experts have highlighted a few key abstracts, which we will cover online as part of CCO’s Independent Conference Coverage of EHA 2022. Remember to check the CCO website often for a downloadable slideset summarizing the data from these studies and then again for a CME-certified online activity featuring expert analyses and perspectives on the clinical implications of the new data.

Top Picks: Lymphomas
Alessandra Tedeschi, MD, identified the following important and potentially practice-changing studies in lymphomas reported at EHA 2022.

  • GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for chronic lymphocytic leukemia (CLL) (abstract LB2365); coprimary endpoints of measurable residual disease negativity and progression-free survival (PFS) were met, with statistically significant improvement in PFS with venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy.
  • ELEVATE-TN: phase III trial of acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil as first-line therapy in CLL (abstract P666); at 5 years of follow-up, acalabrutinib ± obinutuzumab maintained both efficacy and safety benefit with prolonged survival compared with obinutuzumab + chlorambucil.
  • Rosewood: phase II study of zanubrutinib + obinutuzumab (ZO) vs obinutuzumab in patients with R/R follicular lymphoma who previously received ≥2 lines of therapy (abstract S205); primary endpoint was met, with significant improvement of overall response rate with ZO vs obinutuzumab alone, as well as noted improvement in median PFS.
  • ASPEN: phase III trial of zanubrutinib vs ibrutinib in patients with Waldenstrom macroglobulinemia (abstract P1161); long-term follow-up continues to show clinically meaningful efficacy with zanubrutinib and consistently fewer adverse events leading to discontinuation with zanubrutinib vs ibrutinib.

Top Picks: Leukemias
Stéphane de Botton, MD, identified 3 key studies in acute myeloma leukemia (AML) reported at EHA 2022.

  • QuANTUM-First: phase III trial of quizartinib + intensive induction and consolidation vs placebo + intensive induction and consolidation in newly diagnosed FLT3-ITD+ AML (abstract S100); overall survival (OS) was improved with addition of quizartinib for patients with FLT3-ITD+ AML, with a manageable safety profile.
  • AML19: CPX-351 vs FLAG-Ida for younger patients with high-risk AML (abstract S128); exploratory analysis showed similar OS and event-free survival with CPX-351 vs FLAG-Ida but longer duration of remission with CPX-351 in this patient population.
  • Phase III study from EORTC Leukemia Group, CELG, GIMEMA, and German MDS Study Group on comparison of decitabine vs 3+7 chemotherapy followed by allogeneic stem cell transplant for patients 60 years of age or older with AML (abstract S125); OS and rate of allogeneic stem cell transplant was similar with decitabine vs 3+7 chemotherapy, and a better adverse event profile was observed with decitabine.

Top Picks: Multiple Myeloma
Jesús F. San-Miguel, MD, PhD, identified the following key studies in multiple myeloma (MM) reported at EHA 2022.

  • DETERMINATION: phase III trial of lenalidomide/bortezomib/dexamethasone (RVd) ± autologous stem cell transplant followed by lenalidomide maintenance for newly diagnosed MM (abstract LB2366); addition of autologous stem cell transplant to RVd triplet induction + sustained lenalidomide maintenance yielded prolonged median PFS but similar OS.
  • TRIMM-2: phase Ib study of the B-cell maturation antigen (BCMA) bispecific antibody teclistamab in combination with daratumumab in R/R MM (abstract S188); teclistamab + daratumumab showed promising efficacy, and data suggest these agents can be combined safely for patients with R/R MM.
  • CARTBCMA-HCB-01: study of the academic anti-BCMA CAR T-cell therapy ARI0002H using fractionated initial therapy and a booster dose for patients with R/R MM (abstract S103); promising efficacy and safety for this CAR T-cell therapy using fractionated dosing and a second infusion to boost response.
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
BeiGene, Ltd.
Jazz Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings